The multicentre, open-label, two-stage, single-arm, phase 2, PILLAR (PIvotaL Lymphoma triAls of RAD001)-1 study (NCT00702052) assessed the efficacy and safety of everolimus 10 mg/d in adults with confirmed mantle cell lymphoma (MCL) refractory to or intolerant of bortezomib who received ≥1 other antineoplastic agent, either separately or in combination with bortezomib. Primary endpoint was overall response rate (ORR) per investigator review according to the response criteria for malignant lymphoma. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and safety. Fifty-eight patients were enrolled from August 2008-January 2011. Five partial responses were observed (ORR 8Á6%; 90% confidence interval [CI] 3Á5-17Á3%); the study did not meet the prespecified objective of ≥8 objective responses among 57 patients. Median PFS and OS were 4Á4 months (95% CI 3Á5-6Á1) and 16Á9 months (95% CI 14Á4-29Á9), respectively. Grade 3/4 non-haematological toxicities occurred in 70Á7% of patients. Based on laboratory values, grade 3/4 thrombocytopenia, neutropenia and anaemia occurred in 13Á8%, 13Á8% and 8Á6% of patients, respectively. Everolimus demonstrated modest activity and acceptable tolerability in heavily pretreated patients with MCL refractory to or intolerant of bortezomib. Future studies evaluating everolimus in a less refractory population or in combination with other targeted therapies in refractory MCL are warranted.
Mantle cell lymphoma (MCL) is a rare, often aggressive mature B-cell lymphoma representing 5-10% of all nonHodgkin lymphomas (Perez-Galan et al, 2011) . Most MCL are characterized by a t(11;14)(q13;q32) balanced chromosomal translocation of the cyclin D1 gene (CCND1) on chromosome 11 to the immunoglobulin heavy chain enhancer region on chromosome 14, resulting in cyclin D1 overexpression and increased cell proliferation (Perez-Galan et al, 2011) . Aside from this hallmark translocation, MCL frequently involves secondary chromosomal alterations impacting other genes involved in cell cycle regulation and those implicated in DNA damage response, signal transduction and apoptosis (Perez-Galan et al, 2011) .
MCL typically presents as advanced disease, with common extranodal manifestations in the gastrointestinal tract, bone marrow, liver, spleen and Waldeyer ring (Cohen et al, 1998; Romaguera et al, 2003) . Recommended first-line therapy for advanced MCL is rituximab-based chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation in eligible patients (Dreyling et al, 2013; National Comprehensive Cancer Network, Inc, 2013) . Despite high response rates, many patients relapse and often develop chemoresistance. The response duration of conventional chemotherapy in relapsed/refractory MCL is typically short, even after highdose therapy and ASCT (Perez-Galan et al, 2011) . Although a small subset of patients may experience long-term diseasefree survival after non-myeloablative allogeneic stem cell transplantation, curative therapy for MCL remains elusive for the majority of patients (National Comprehensive Cancer Network, Inc, 2013) . The first novel agent approved by the United States Food and Drug Administration as second-line therapy for MCL was bortezomib (Fisher et al, 2006; Goy et al, 2009; ). In the phase 2 PINNA-CLE study of MCL patients previously treated with 1 or 2 lines of therapy (N = 155), bortezomib showed a 32% overall response rate (ORR), 9Á2-month median duration of response and 6Á7-month median time to progression (Goy et al, 2009) . Based on the results of the phase II EMERGE study (Goy et al, 2013) , lenalidomide was approved in the United States for the treatment of patients who relapsed after, or were refractory to, bortezomib. Although other cytotoxic regimens are used in this setting, no consensus regarding the optimal strategy exists.
Dysregulation of the mammalian target of rapamycin (mTOR) pathway is frequently observed in MCL (Rizzatti et al, 2005; Peponi et al, 2006; Rudelius et al, 2006; Dal et al, 2008) , and the cap-dependent translation necessary for cyclin D1 expression is regulated by this pathway (Bjornsti & Houghton, 2004; Schatz, 2011) . In vitro data have established that inhibiting mTOR with everolimus induces cell cycle arrest and reduces 4E-BP1 phosphorylation (Haritunians et al, 2007) . Similar findings have been observed in other studies of everolimus and the mTOR inhibitors rapamycin and temsirolimus (Galimberti & Petrini, 2010; Rosich et al, 2012) . In one phase 2 study (N = 77), oral everolimus 10 mg/d produced a 30% ORR in patients with relapsed, aggressive lymphoma, including a 32% ORR in patients with MCL (n = 19) . Everolimus was generally well tolerated, and most toxicities were manageable with temporary dose adjustment. A second phase 2 study also found everolimus to be well tolerated with clinical activity against relapsed/refractory MCL (Renner et al, 2012) . In a randomized, open-label, phase 3 study (N = 162), intravenous temsirolimus 175 mg/week for 3 weeks followed by 75 mg/week thereafter (175/75-mg regimen) significantly prolonged progression-free survival (PFS) compared with the investigator's choice of 1 of 11 prospectively defined singleagent treatment options (4Á8 months vs. 1Á9 months; P = 0Á009) and increased ORR (22% vs. 2%; P = 0Á0019) (Hess et al, 2009) . Although thrombocytopenia, asthenia and diarrhoea occurred more often with temsirolimus than the investigator's choice (P ≤ 0Á041), the overall safety profile was considered manageable. Based on these results, temsirolimus was approved by the European Medicines Agency for the treatment of relapsed/refractory MCL (http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000799/WC500039912.pdf).
This phase 2 study was designed to evaluate everolimus efficacy and safety in patients with MCL who were intolerant of or refractory to bortezomib.
Methods

Study design and patients
PILLAR (PIvotaL Lymphoma triAls of RAD001)-1 was a multicentre, open-label, two-stage, single-arm, phase 2 study conducted in the United States (ClinicalTrials.gov identifier NCT00702052). Inclusion criteria included age ≥18 years; histopathologically confirmed (central pathology review) MCL with staining for cyclin D1 overexpression or cytogenetic evidence of the t(11;14)(q13;q32) translocation, documented bortezomib-refractory disease or bortezomib intolerance and receipt of ≥1 other antineoplastic agent given either separately or with bortezomib. Patients were considered bortezomib refractory if they had documented radiological progression on or within 12 months of the last bortezomib dose when given alone or as the last component of combination therapy including bortezomib. Patients were considered bortezomib intolerant if they discontinued bortezomib due to documented toxicity. Other inclusion criteria included ≥1 nodal site of measurable disease >2Á0 cm; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; life expectancy ≥3 months; and adequate bone marrow, hepatic and renal function. Exclusion criteria included unresolved grade 3/4 toxicity from antineoplastic therapies, anticancer therapy or other investigational agent taken within 4 weeks of study start, previous mTOR inhibitor treatment, previous allogeneic stem cell transplant, presence or history of central nervous system lymphoma, chronic immunosuppressive therapy 
Procedures
Patients received oral everolimus 10 mg once daily until disease progression per investigator review, unacceptable toxicity, death or discontinuation for other reason. Dose reductions and/or interruptions according to an algorithm outlined in the study protocol were permitted for intolerable toxicity.
Computed tomography scan of the chest, abdomen and pelvis with radiological tumour evaluation was performed at screening, every 8 weeks (AE1 week) for the first year of study treatment and every 12 weeks (AE1 week) thereafter until initiation of new anticancer therapy. Response was also assessed at end of treatment. Adverse events (AEs) were monitored continuously throughout the study and for 28 d after the last study drug dose. Serum chemistry, coagulation, complete blood count (CBC) and serum lipid profiles were assessed at baseline, every 4 weeks during treatment and at the end of treatment. Routine CBCs were also assessed every 2 weeks for the first 12 weeks. All patients were followed monthly for survival until the date of final analysis (20 April, 2012) .
Venous blood samples (2 ml) for pharmacokinetic analysis were collected in EDTA-containing tubes pre-dose on day 15 and at times of tumour assessment to assess everolimus trough concentrations (C min ). Samples were also collected at 1 and 2 h post-dose on day 15 to capture the near-maximum everolimus concentration (C max ). If samples were not obtained at the specified visit, they were collected at the next scheduled visit. On days of sample collection, everolimus administration was supervised by study centre personnel. All blood samples were stored at À20°C within 1 h of collection. Everolimus concentrations in whole blood were determined at a central laboratory (WuXi Apptec, Shanghai, China) using a liquid chromatography-mass spectrometry method following liquid extraction (lower limit of quantification, 0Á3 ng/ml).
Statistical analysis
Efficacy was assessed in the full analysis set (i.e. all patients who received ≥1 dose of study drug). Safety was assessed in the safety set (i.e. all patients who received ≥1 dose of study drug and had ≥1 valid postbaseline safety assessment).
The primary study endpoint was ORR, assessed by the investigator and defined as the percentage of patients with a complete response (CR) or partial response (PR) according to response criteria for malignant lymphoma based on Cheson (Cheson et al, 1999; Cheson, 2007) . Sensitivity analyses were based on central radiology review. Secondary endpoints included duration of response (DOR), PFS, OS and safety and tolerability. DOR was defined as the time from first documented response (CR or PR) to the time of first documented progression or death due to lymphoma; patients without disease progression or who died from causes other than lymphoma were censored (indicated by "+") at the time of last valid tumour assessment. PFS was defined as the time from start of study treatment to the time of first documented disease progression or death due to any cause; patients were censored at the time of last valid tumour assessment in the absence of progression or death. OS was defined as the time from start of study treatment to the time of death due to any cause; patients lost to follow-up or alive at the analysis cut-off date were censored at their last contact date. AEs and laboratory abnormalities were assessed according to the Common Terminology Criteria for Adverse Events, version 3Á0 (http://ctep.cancer.gov/protocolDevelopment/electronic_ applications/docs/ctcaev3.pdf).
The Kaplan-Meier method was used to analyse timeto-event endpoints and to estimate median values and corresponding 95% confidence intervals (CIs). A Cox proportional model was used to analyse the relationship between average C min and time to disease progression and select AEs. Average C min was calculated as a time average over the trial period until the event, accounting for dose adjustments.
Simon's 2-stage minimax design was adopted to permit early termination for futility. The targeted ORR in the full analysis set was 20%; an ORR ≤7% would preclude further investigation. Assuming a 5% significance level and 90% power, 34 patients were to receive study treatment in the first stage. If ≤2 patients achieved response, the study was to be terminated. Otherwise, 23 additional patients were to be enrolled and receive treatment. If ≥8/57 enrolled patients experienced a response, everolimus would be considered of clinical interest in this population.
Role of the funding source
The sponsor helped to design the study and to collect, analyse and interpret the data and provided funding for medical writing assistance in the preparation of this report. As authors, employees of the sponsor contributed to the decision to submit the manuscript. All authors had access to the data and approved the manuscript for submission.
Results
Between 22 August, 2008, and 18 January, 2011, 58 patients were enrolled from 26 centres in the United States and received ≥1 everolimus dose. Table I shows the baseline demographics and disease characteristics of the patients. Forty-nine patients (84Á5%) were bortezomib refractory and eight patients (13Á8%) were intolerant of bortezomib; one patient could not be classified as either because disease progression occurred >12 months after the last bortezomib dose. At initial diagnosis, 19Á0% and 67Á2% of patients presented with stage III and IV disease, respectively. Before enrolment, all patients received >1 antineoplastic therapy, including 74Á1% who received ≥3 and 20Á7% who received ASCT. All patients were included in both the full analysis and safety sets. Median follow-up duration (time from median treatment start date to final analysis date [20 April, 2012] ) was 23Á2 months. At final analysis, all patients discontinued treatment, most commonly because of disease progression or AEs (Table II) . After study drug discontinuation, 42 patients (72Á4%) received further antineoplastic therapy.
As of 26 April, 2010, stage 1 was declared successful, with 3/26 enrolled patients achieving PR per investigator review (before the 34-patient target); this permitted uninterrupted recruitment in stage 2. At final analysis and per investigator review, best overall response was PR in 5 patients (ORR 8Á6%; 90% CI 3Á5-17Á3%) (Table III) . DOR ranged from 0Á7-11Á1+ months. Four patients proceeded to stem cell transplantation following study completion (allogeneic transplantation, n = 3; unknown type, n = 1). Median PFS per investigator review was 4Á4 months (95% CI 3Á5-6Á1 months) (Fig. 1A) . Median OS was 16Á9 months (95% CI 14Á4-29Á9) (Fig. 1B) .
In a sensitivity analysis based on central radiology review, six patients achieved PR (ORR 10Á3%; 90% CI 4Á6-19Á4%) (Table III) . Per central review, DOR ranged from 1Á6+ months to 13Á2+ months and median PFS was 5Á2 months (95% CI 4Á0-7Á1 months).
Median everolimus treatment duration and dose intensity were 87Á0 d and 9Á2 mg/d, respectively. Dose interruptions and/or reductions were required by 34 patients (58Á6%), most commonly as the result of AEs (55Á2%). All patients experienced ≥1 AE, including 81Á0% who experienced ≥1 grade 3/4 AE (Table IV) . Grade 3/4 non-haematological AEs occurred in 70Á7% of patients and included pneumonia (8Á6%), abdominal pain (8Á6%) and fatigue (6Á9%). Pneumonitis of all grades occurred in 7 patients (12Á1%), with a greatest severity of grade 3 (n = 3; 5Á2%); 3 of these 7 patients discontinued everolimus. Based on laboratory values, 57 patients (98Á3%) experienced a haematological AE, including 23 (39Á7%) who experienced a grade 3/4 event ( Table V) . The most frequently reported haematological laboratory abnormality was anaemia (84Á5% any grade, 8Á6% grade 3/4), followed by thrombocytopenia (75Á9% any grade, 13Á8% grade 3/4). Seven deaths (all due to lymphoma) occurred within 28 days of the last everolimus dose.
Everolimus C min values, assessed by actual dose at time of assessment, were mostly stable over time, although fluctuation 
Discussion
In the phase 2 PILLAR-1 study of 58 patients with heavily pretreated MCL refractory to or intolerant of bortezomib, 5 patients experienced PR with everolimus, which was below the targeted ≥8 responses out of 57 patients required to declare everolimus worthy of further study in this population. The ORR was 8Á6% (90% CI 3Á5-17Á3%), which was lower than the 32% and 20% (Renner et al, 2012) ORRs reported in other phase 2 studies of everolimus for previously treated MCL, the 41% (Ansell et al, 2008) and 38% (Witzig et al, 2005) ORRs reported in the phase 2 studies of temsirolimus and the 22% ORR reported in the phase 3 temsirolimus study (Hess et al, 2009) . It is interesting to note that, although median PFS in PILLAR-1 was less than that reported in the phase 2 study of temsirolimus published by Witzig et al (2005) (4Á4 months and 6Á5 months, respectively), it was similar to Data are given as number (%). *Denominator is the number of patients who discontinued the posttreatment evaluation period. that reported by Hess et al (2009) for the 175/75-mg temsirolimus regimen in the phase 3 trial (4Á8 months). The PFS observed in PILLAR-1 was also similar to the 4Á0-month median PFS recently reported in the phase 2 EMERGE study of lenalidomide for patients who relapsed after or were refractory to bortezomib (Goy et al, 2013) . Additionally, the median OS in PILLAR-1 was longer than that reported in any of the temsirolimus trials (16Á9 months vs. 12 months (Witzig et al, 2005) , 14 months (Ansell et al, 2008) and 12Á8 months with temsirolimus 175/75 mg (Hess et al, 2009) ). Although it is not clear why the PILLAR-1 ORR was lower than in other studies of mTOR inhibitors in this setting, it is possible that the enrolment of a high percentage of patients with bortezomibrefractory disease (84Á5%) resulted in a more heavily pretreated, higher-risk population than that enrolled in previous studies of mTOR inhibitors for relapsed/refractory MCL. Only 23% of patients in the phase 3 temsirolimus study had prior bortezomib therapy (Hess et al, 2009) . Although not reported, the percentage of patients previously treated with bortezomib in the phase 2 temsirolimus trials was probably very low because these studies were conducted before bortezomib was approved for treating MCL (Witzig et al, 2005; Ansell et al, 2008) . In PILLAR-1, 74Á1% of patients received ≥3 previous treatment regimens, similar to the 78Á3% of patients enrolled in the EMERGE study who received ≥3 previous treatment regimens (Goy et al, 2013) . In the trials of temsirolimus, the median number of therapies ranged from 3 (Witzig et al, 2005; Hess et al, 2009 ) to 4 (Ansell et al, 2008) . Compared with the phase 2 temsirolimus trial published by Witzig et al (2005) , almost twice as many patients in PILLAR-1 had undergone previous ASCT (11% vs. 20Á7%). It is also clear that MCL is a very heterogeneous disease. Previous studies (Rosenwald et al, 2003; Katzenberger et al, 2008) have shown that the proliferation index can be used to sub-classify MCL into different clinical and prognostic entities. Patients with more proliferative disease, as determined Table IV . Non-haematological adverse events occurring in >10% of patients regardless of relationship to study drug in the safety set. by gene expression profiling or Ki-67 staining, are known to have a worse prognosis and more aggressive disease. Patients with a lower proliferative index are known to have a substantially better prognosis and may be managed in a manner similar to those with other indolent lymphomas (Martin & Leonard, 2011) . Given this biological diversity, it is conceivable that variability in the proportion of patients with highly versus less proliferative disease could influence the outcome of a drug known to have a marked impact on this underlying biology.
Another possible explanation related to MCL heterogeneity is that fewer patients in PILLAR-1 may have had disease with constitutive mTOR pathway activation, rendering them less responsive to mTOR inhibition with everolimus. Although predictive biomarkers for efficacy of mTOR inhibitors in lymphoma have not been clearly established, preclinical data suggest that tumour cells with constitutive mTOR pathway activation are more responsive to mTOR inhibitors (Di Nicolantonio et al, 2010; Weigelt et al, 2011; Meric-Bernstam et al, 2012) . Supportive clinical data come from whole genome and capture-based sequencing performed on DNA samples collected from 14 patients enrolled in a phase 2 study of everolimus for metastatic bladder cancer (Iyer et al, 2012) . In that study, patients whose tumours harboured mutations in TSC1, a gene encoding one half of the hamartin/tuberin tumour suppressor complex that lies upstream of mTOR, had a longer duration of everolimus therapy than those with TSC1 wild-type tumours (7Á7 vs. 2Á0 months; P = 0Á004) and a significantly longer time to recurrence (4Á1 vs. 1Á8 months; P = 0Á001).
Everolimus demonstrated acceptable tolerability in this heavily pretreated, bortezomib-refractory/intolerant population, with no new safety findings. The toxicities observed were similar to those previously reported in patients receiving mTOR inhibitors, were reversible and were effectively managed with either dose adjustment or use of supportive therapies. The incidence of grade 3/4 non-haematological AEs in this study (70Á7%) was somewhat higher than that reported by Witzig et al (2011) (53%) , although the incidence of the most commonly observed grade 3/4 AEs was similar . Conversely, the incidence of grade 3/4 haematological AEs in this study (39Á7% as assessed by laboratory abnormalities) was somewhat less than the 56% incidence reported by Witzig et al (2011) . Additionally, rates of grade 3/4 thrombocytopenia, neutropenia and anaemia in PILLAR-1 (13Á8%, 13Á8% and 8Á6%, respectively) compare favourably with those reported previously (38%, 18% and 14%, respectively) . Individual grade 3/4 haematological AEs were also more common in the trials of temsirolimus for MCL, with 39-66% of patients experiencing thrombocytopenia, 14-26% experiencing anaemia and 15-29% experiencing neutropenia (Witzig et al, 2005; Ansell et al, 2008; Hess et al, 2009) .
Although PILLAR-1 demonstrated moderate clinical activity for everolimus monotherapy in bortezomib-refractory or intolerant MCL, the activity observed in this study and previously noted with other mTOR inhibitors (Witzig et al, 2005 Ansell et al, 2008; Hess et al, 2009; Renner et al, 2012) suggests a possible role for mTOR inhibition in MCL. It is possible that everolimus may demonstrate improved efficacy in a less refractory population or in patients whose disease demonstrates constitutive mTOR pathway activity. Given the profound prognostic impact of the proliferation index in MCL and the likelihood that different MCL subsets will respond differently to drugs targeting pathways involved in cellular proliferation, future MCL studies should include some measurement of the proliferation index. Combination therapy with everolimus should also be considered. In human MCL cell lines, synergistic cytotoxic activity was observed when everolimus was combined with various agents already used to treat MCL, including doxorubicin, vincristine, paclitaxel, rituximab, bortezomib and vorinostat (Haritunians et al, 2007) . Preclinical data from human MCL cell lines also suggest that simultaneously inhibiting PI3K and mTOR could lead to more effective MCL treatment (Civallero et al, 2012; Kim et al, 2012) . Data from clinical trials of temsirolimus-based combination therapy appear to confirm the merit of assessing everolimus-based combinations. In a phase 2 study of patients with relapsed or refractory MCL, temsirolimus plus rituximab was associated with acceptable tolerability, provided an ORR of 59Á4% and median time to progression of 9Á7 months and was associated with a median OS of 29Á5 months . Preliminary data from a phase I/II study also suggest a possible benefit for the combination of temsirolimus, bendamustine and rituximab (Hess et al, 2011) . Ongoing trials are assessing temsirolimus in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), R-FC (rituximab, fludarabine, cyclophosphamide) or R-DHA (rituximab, high-dose cytarabine, dexamethasone (NCT01389427); bortezomib, rituximab and dexamethasone (NCT01381692); and lenalidomide (NCT01076543); everolimus is being assessed in combination with panobinostat (NCT00918333 and NCT00967044), idelalisib (NCT01088048) and lenalidomide (NCT01075321).
In conclusion, everolimus monotherapy demonstrated modest activity and acceptable tolerability in patients with heavily pretreated, bortezomib-refractory or -intolerant MCL. Future studies exploring everolimus as monotherapy in a less refractory population or in combination with chemotherapy or other targeted therapies for refractory MCL are warranted. 
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